Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00051116
Status:
COMPLETED
Last Update Posted:
2009-09-23
First Post:
2003-01-03
Brief Title:
A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma
Sponsor:
Celgene Corporation
Organization:
Celgene
Organization Data
Organization:
Celgene
Class:
INDUSTRY
Study ID:
CC-5013-MM-008
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Celgene Corporation
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Robert Knight MD - VP Hematology
Old Organization:
Celgene Corporation